公开(公告)号：US20140284468A1

公开(公告)日：2014-09-25

申请号：US14295783

申请日：2014-06-04

Applicant: Biodesix, Inc.

Inventor： Julia Grigorieva ,  Heinrich Röder ,  Maxim Tsypin

IPC: G01N33/68 ,  H01J49/40

CPC classification number: G01N33/6848 ,  G01N33/57415 ,  G01N2800/52 ,  G16C20/20 ,  G16C20/70 ,  G16H10/40 ,  H01J49/00 ,  H01J49/40 ,  Y02A90/22

Abstract: Methods using mass spectral data analysis and a classification algorithm provide an ability to determine whether a solid epithelial tumor cancer patient is likely to benefit from a therapeutic agent or a combination of therapeutic agents targeting agonists of the receptors, receptors or proteins involved in MAPK (mitogen-activated protein kinase) pathways or the PKC (protein kinase C) pathway upstream from or at Akt or ERK/JNK/p38 or PKC, such as therapeutic agents targeting EGFR and/or HER2. The methods also provide the ability to determine whether the cancer patient is likely to benefit from the combination of a therapeutic agent targeting EFGR and a therapeutic agent targeting COX2; or whether the cancer patient is likely to benefit from the treatment with an NF-κB inhibitor.

Abstract translation: 使用质谱数据分析和分类算法的方法提供了确定固体上皮肿瘤癌症患者是否可能受益于治疗剂或靶向受体，受体或参与MAPK的蛋白质（促分裂原）的治疗剂的组合的能力 激活的蛋白激酶）途径或在Akt或ERK / JNK / p38或PKC上游的PKC（蛋白激酶C）途径，例如靶向EGFR和/或HER2的治疗剂。 所述方法还提供了确定癌症患者是否可能受益于靶向EFGR2的治疗剂与靶向COX2的治疗剂的组合的能力的能力; 或者癌症患者是否可能受益于用NF-κB抑制剂治疗。